Skip to content

Foundayo vs Rybelsus: uses, how to take them, doses and cost

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Foundayo vs Rybelsus compares two daily tablets approved for different conditions. Foundayo (orforglipron, Eli Lilly) is approved for long-term weight reduction. Rybelsus (semaglutide, Novo Nordisk) is approved for type 2 diabetes. Foundayo self-pay through LillyDirect runs from $149 to $299 a month. Rybelsus has a savings offer, as little as $25 with commercial coverage.

Source: LillyDirect self-pay

Key takeaways

  • Foundayo is approved for long-term weight reduction in adults. Rybelsus is approved for adults with type 2 diabetes.
  • Rybelsus needs an empty stomach and a 30-minute wait every morning. Foundayo goes with or without food.
  • Paying cash? LillyDirect sells Foundayo from $149 a month. Our only Rybelsus price is the commercial-insurance savings offer.
  • On Medicare, Rybelsus goes through Part D. Foundayo for weight goes through the GLP-1 Bridge, closed to people with type 2 diabetes.
  • No label converts a Rybelsus dose into a Foundayo dose. Your prescriber decides the starting dose and timing.

Foundayo vs Rybelsus, side by side

From each FDA label and our verified price records
FoundayoRybelsus
Active ingredientorforglipronsemaglutide
MakerEli Lilly and CompanyNovo Nordisk
FDA-approved uses
  • reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events
How it is takendaily (tablet)daily (tablet)
Strengths0.8 to 17.2 mg3 to 14 mg
Label starting dose
  • 0.8 mg daily
  • 3 mg daily
Cheapest verified self-pay$299 per fill at 17.2 mg
LillyDirect self-pay
No self-pay price listed
With covering commercial insurance$25 with the manufacturer card$25 with the manufacturer card
Medicare GLP-1 BridgeYes: Tablet (once daily)No
LabelRevised: 7/2026 (DailyMed version 10)Revised: 1/2026 (DailyMed version 14)
Foundayo: most common reactions on the label · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
Reaction17.2 mgPlacebo
Nausea35%10%
Diarrhea25%11%
Constipation24%9%
Vomiting24%4%
Abdominal pain14%7%
Dyspepsia13%4%
Rybelsus: most common reactions on the label · Adults with type 2 diabetes in 2 placebo-controlled trials of semaglutide tablets (Rybelsus); mean duration of exposure was 41.8 weeks. The table excludes hypoglycemia.
ReactionSemaglutide tablets 14 mgPlacebo
Nausea20%6%
Abdominal Pain11%4%
Diarrhea10%4%
Decreased appetite9%1%
Vomiting8%3%
Constipation5%2%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Foundayo and Rybelsus get compared because they look alike from a distance: a GLP-1 medicine in a tablet, one a day, no needles. Up close, they have little in common. They hold different drugs, their labels approve them for different conditions, and one comes with a strict morning routine the other doesn’t need. This page compares them using the FDA labels (Revised: 7/2026 (DailyMed version 10) for Foundayo, Revised: 1/2026 (DailyMed version 14) for Rybelsus) and our price records.

Foundayo or Rybelsus: which suits whom?

The reason you’re being treated answers most of this before form or price come into it.

  • You’re being treated for weight. Foundayo is approved for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition. It isn’t approved for type 2 diabetes.
  • You have type 2 diabetes. Rybelsus is approved for adults with type 2 diabetes, for blood sugar control and for reducing major cardiovascular events (serious heart and blood vessel events) in those at high risk. It has no weight-loss use.
  • A fixed morning routine would be hard to keep. Foundayo’s label is more forgiving: with or without food, and no waiting period.
  • You’re paying cash. Foundayo has a published self-pay price, from $149 a month.
  • You’re on Medicare. The routes don’t overlap. Rybelsus goes through Part D as a diabetes medicine. Foundayo for weight management goes through the Medicare GLP-1 Bridge, which is closed to people with type 2 diabetes.

A few things are the same: each is a once-daily tablet, swallowed whole, no more than one a day, with no refrigerator needed. If you have type 2 diabetes and also want treatment for weight, ask your prescriber which label fits what you’re being treated for, because that decides which coverage route applies to you.

What is each approved for?

Foundayo is orforglipron, made by Eli Lilly. It has one approved use: to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition.

Rybelsus is semaglutide in tablet form, made by Novo Nordisk. It has two approved uses, both in adults with type 2 diabetes: to improve blood sugar control alongside diet and exercise, and to reduce the risk of major adverse cardiovascular events in those at high risk for them.

For the semaglutide brand with a weight-reduction use, see Rybelsus vs Wegovy.

How do you take each tablet?

This is the difference you’d feel every day.

Foundayo. The label’s instructions are brief: one tablet once daily, with or without food, swallowed whole, never more than one tablet a day.

Rybelsus. The label’s instructions are exact:

  • once daily, in the morning, on an empty stomach;
  • with up to 4 ounces of plain water and no other liquid;
  • swallowed whole, not split, crushed or chewed;
  • then a wait of at least 30 minutes before food, other drinks or other oral medicines;
  • never more than one tablet a day.

Both are stored at room temperature, and neither needs a refrigerator. The Rybelsus label says to keep the tablets in the original bottle until you use them, to protect them from moisture.

Interactions each label names

The two labels flag different medicines, so bring your full medicine list to the appointment.

  • Foundayo: with a strong CYP3A4 inhibitor (a type of medicine that slows how the body clears some drugs), the maximum Foundayo dose is 9 mg once daily. Strong CYP3A4 inhibitors that also inhibit OATP1B, and strong CYP3A4 inducers (which speed that clearing up), should be avoided. Simvastatin shouldn’t exceed 20 mg once daily. If you take birth control pills, the label advises switching to a non-oral method or adding a barrier method for 30 days after starting and after each dose increase.
  • Rybelsus: in a drug interaction study, levothyroxine (a thyroid medicine) exposure rose 33% when it was taken with semaglutide tablets.

How do the doses compare?

Foundayo comes in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg. The label starts at 0.8 mg once daily, moves to 2.5 mg after at least 30 days and to 5.5 mg after at least 30 more. From there, the dose may be raised to 9 mg, 14.5 mg or 17.2 mg, each after at least 30 days, based on response and tolerability. The maximum is 17.2 mg.

Rybelsus comes in 3 mg, 7 mg, 14 mg. Days 1 to 30 are at 3 mg, which the label says is not effective for blood sugar control. Days 31 to 60 are at 7 mg. From day 61, the dose may be raised to 14 mg if more blood sugar control is needed.

Both move in 30-day steps. The milligram figures belong to different molecules and can’t be set against each other. The titration schedule tool puts either on a calendar.

The missed-dose rules differ too, and the missed dose tool covers both.

What does each cost?

Foundayo, per 30-day supply:

  • LillyDirect self-pay: $149 for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg and 17.2 mg. The 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026.
  • Savings card with commercial insurance that covers Foundayo: as little as $25 per fill.
  • Medicare GLP-1 Bridge: a $50 monthly copay for those who qualify.
  • List price (the full price before any discount): $649 a month.

Rybelsus: one price. With commercial insurance that covers Rybelsus, the savings offer lowers the cost to as little as $25. Novo Nordisk also states that Rybelsus is being replaced by the Ozempic pill and that existing Rybelsus savings offers can be used for Ozempic.

Starting Foundayo at 0.8 mg and stepping up every 30 days to 17.2 mg, your first year through LillyDirect comes to $3,188 with on-time refills. The Foundayo price guide, the Rybelsus cost page and the cost calculator go further.

Does insurance or Medicare cover them?

Commercial plans treat a diabetes medicine and a weight-management medicine very differently. Rybelsus for type 2 diabetes is commonly covered, with prior authorization (the plan’s approval before it pays) or step requirements (trying another medicine first) that vary. Foundayo depends on whether your plan covers weight-management drugs at all, and some employers exclude the category. Call the number on your insurance card and ask about the exact brand and your diagnosis.

Medicare separates them completely:

  • Rybelsus. CMS lists type 2 diabetes as an indication eligible for Part D coverage. From January 1, 2027, the negotiated Medicare price for a 30-day supply of semaglutide (Ozempic, Rybelsus, Wegovy) is $274. Your copay will still depend on your plan.
  • Foundayo. The Part D statute excludes drugs when used for weight loss, so a Part D plan won’t normally pay for it. The Medicare GLP-1 Bridge is the exception: eligible people with Part D pay a $50 copay for a one-month supply through December 31, 2027. People with type 2 diabetes aren’t eligible for the Bridge.

The Bridge eligibility checker and the Bridge guide explain who qualifies.

How do the side effects compare?

Both labels list mostly gastrointestinal (stomach and bowel) reactions. The trials behind them enrolled different people for different conditions, weight management for Foundayo and type 2 diabetes for Rybelsus. So the rates are reported separately here, and they aren’t a ranking.

Foundayo. In the label’s pool of Trials 1 and 2, up to 72 weeks, nausea was reported by 26, 34 and 35 percent of people on 5.5 mg, 9 mg and 17.2 mg, versus 10 percent on placebo. Across both trials, 8 percent of people on Foundayo stopped treatment permanently because of adverse reactions, compared with 3 percent on placebo.

Rybelsus. In the label’s placebo-controlled trials, nausea was reported by 11 percent of patients on 7 mg and 20 percent on 14 mg, versus 6 percent on placebo. A greater share of patients on 14 mg (8%) and 7 mg (4%) stopped treatment because of gastrointestinal reactions than on placebo (1%).

Both labels carry a boxed warning about the risk of thyroid C-cell tumors. Neither drug should be used by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or with MEN 2 (an inherited condition linked to it). If that describes you, tell your prescriber.

Can you switch between Foundayo and Rybelsus?

A move between these two usually means the reason for treatment has changed, and the labels don’t describe it. The Foundayo label gives no instructions for switching from another GLP-1 medicine. It states only its starting dose. The Rybelsus label’s switching instructions cover Ozempic tablets and the Ozempic pen, nothing else. And the Foundayo label says it shouldn’t be used together with another GLP-1 receptor agonist.

So no label pairs a Rybelsus strength with a Foundayo strength, and we don’t convert doses between drugs. Your prescriber decides the starting dose and the timing. Your coverage will need checking again too, because the diagnosis behind the prescription is different. The switching guides and the switching planner show what each label says, and more pairings are on the comparison hub.

Frequently asked questions

Is Foundayo like Rybelsus?

Both are GLP-1 receptor agonist tablets taken once a day, and that's where the likeness stops. Foundayo contains orforglipron and is approved for long-term weight reduction in adults. Rybelsus contains semaglutide and is approved for adults with type 2 diabetes. They come from different makers, in different strengths, with different instructions about food.

Do you have to take Foundayo on an empty stomach like Rybelsus?

No. The Foundayo label says to take it once daily with or without food. The Rybelsus label says to take it in the morning on an empty stomach with up to 4 ounces of plain water. Then wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.

Is Rybelsus approved for weight loss?

No. The Rybelsus label lists two uses, both in adults with type 2 diabetes: improving blood sugar control, and reducing major cardiovascular events in those at high risk. Foundayo's label is the reverse. It covers long-term weight reduction in adults with obesity or overweight with a weight-related condition, and Foundayo isn't approved for type 2 diabetes.

Which is cheaper, Foundayo or Rybelsus?

It depends on how you pay. Without insurance, Foundayo has LillyDirect prices from $149 to $299 a month. With commercial insurance that covers the medicine, each has a savings offer that lowers a fill to as little as $25.

Can I take Foundayo and Rybelsus together?

The Foundayo label says using it together with another GLP-1 receptor agonist isn't recommended, and Rybelsus is a GLP-1 receptor agonist. If your prescriber changes you from one to the other, the label gives no dose conversion. The Foundayo label states only its own starting dose of 0.8 mg once daily.

Sources (31)

  1. 1.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “Take FOUNDAYO orally once daily, with or without food.”
  2. 2.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “Swallow tablets whole. Do not break, crush, or chew.”
  3. 3.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “Do not take more than one tablet per day.”
  4. 4.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily.”
  5. 5.
    FDA label (DailyMed): Foundayo prescribing information, section 2.1
    “The maximum dosage of FOUNDAYO is 17.2 mg once daily.”
  6. 6.
    FDA label (DailyMed): Foundayo prescribing information, section 16.2
    “Store FOUNDAYO at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].”
  7. 7.
    FDA label (DailyMed): Foundayo prescribing information, section 2.2
    “The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].”
  8. 8.
    FDA label (DailyMed): Foundayo prescribing information, section 2.2
    “Avoid strong CYP3A4 inhibitors that also inhibit OATP1B when taking FOUNDAYO. Avoid strong CYP3A4 inducers when taking FOUNDAYO.”
  9. 9.
    FDA label (DailyMed): Foundayo prescribing information, section 7.2, Table 3
    “Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO.”
  10. 10.
    FDA label (DailyMed): Foundayo prescribing information, section 7.3
    “Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.”
  11. 11.
    FDA label (DailyMed): Foundayo prescribing information, section 1
    “Concomitant use with another GLP-1 receptor agonist is not recommended.”
  12. 12.
    FDA label (DailyMed): Foundayo prescribing information, section 4
    “FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
  13. 13.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
    “Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water”
  14. 14.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
    “After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
  15. 15.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
    “Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.”
  16. 16.
  17. 17.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.2
    “Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).”
  18. 18.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 16
    “Store RYBELSUS and OZEMPIC tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store and dispense in the original bottle.”
  19. 19.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 16
    “Store tablets in the original bottle until use to protect tablets from moisture. Store product in a dry place away from moisture.”
  20. 20.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 7.2
    “Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study”
  21. 21.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
    “A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  22. 22.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  23. 23.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  24. 24.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.